MCID: ALM001
MIFTS: 56

Al Amyloidosis

Categories: Rare diseases, Metabolic diseases, Blood diseases, Neuronal diseases, Genetic diseases, Nephrological diseases, Immune diseases, Bone diseases

Aliases & Classifications for Al Amyloidosis

MalaCards integrated aliases for Al Amyloidosis:

Name: Al Amyloidosis 49
Primary Systemic Amyloidosis 49 69
Primary Amyloidosis 49 69
Hereditary Amyloid Nephropathy Due to Lysozyme Variant 55
Familial Amyloid Nephropathy Due to Lysozyme Variant 55
Hereditary Renal Amyloidosis Due to Lysozyme Variant 55
Familial Renal Amyloidosis Due to Lysozyme Variant 55
Immunoglobulin Deposition Disease 69
Primary Systemic Al Amyloidosis 49
Amyloidosis Primary Systemic 49
Light Chain Amyloidosis 49
Primary Al Amyloidosis 49
Systemic Al Amyloidsis 49
Lysozyme Amyloidosis 55
Amyloidosis Primary 51
Alys Amyloidosis 55
Amyloidosis Al 49

Characteristics:

Orphanet epidemiological data:

55
alys amyloidosis
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide);

Classifications:



Summaries for Al Amyloidosis

NIH Rare Diseases : 49 AL amyloidosisis the most common form of amyloidosis, a group of disorders in which an abnormal protein called amyloid builds up in tissues and organs. The signs and symptoms of AL amyloidosis vary among patients because the build up may occur in the tongue, intestines, muscles, joints, nerves, skin, ligaments, heart, liver, spleen, or kidneys. To diagnose AL amyloidosis, healthcare professionals use blood or urine tests to identify signs of amyloid protein and a biopsy to confirm the diagnosis. Treatment may include chemotherapy directed at the abnormal plasma cells, stem cell transplantation, or other treatments based on which symptoms have developed. Last updated: 7/17/2015

MalaCards based summary : Al Amyloidosis, also known as primary systemic amyloidosis, is related to amyloidosis and hereditary amyloidosis, and has symptoms including renal insufficiency, proteinuria and nephrotic syndrome. An important gene associated with Al Amyloidosis is LYZ (Lysozyme), and among its related pathways/superpathways are Innate Immune System and Cell adhesion_Cell-matrix glycoconjugates. The drugs Dexamethasone and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver.

Related Diseases for Al Amyloidosis

Diseases in the Amyloidosis family:

Al Amyloidosis Amyloidosis Aa
Hereditary Amyloidosis Primary Localized Amyloidosis
Ah Amyloidosis

Diseases related to Al Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 amyloidosis 30.8 LYZ TTR
2 hereditary amyloidosis 29.1 LYZ TTR
3 amyloidosis, primary localized cutaneous, 1 12.3
4 amyloidosis, primary localized cutaneous, 2 12.3
5 primary cutaneous amyloidosis 11.9
6 myeloma, multiple 11.6
7 light chain deposition disease 11.1
8 primary localized amyloidosis 11.1
9 amyloidosis, hereditary, transthyretin-related 10.8
10 hepatitis 10.1
11 factor x deficiency 10.1
12 nephrotic syndrome 10.0
13 lymphoma 10.0
14 venous insufficiency 9.9 MMP1 VWF
15 cholestasis 9.9
16 chronic ulcer of skin 9.9 MMP1 TTR
17 immune system disease 9.9 IL3 VWF
18 varicose veins 9.9 MMP1 VWF
19 blood group, i system 9.9
20 macroglossia 9.9
21 infantile liver failure syndrome 1 9.9
22 glomerulonephritis 9.9
23 leukemia 9.9
24 mediastinitis 9.9
25 neuropathy 9.9
26 macroglobulinemia 9.9
27 endotheliitis 9.9
28 lymphangiosarcoma 9.8 LYZ VWF
29 autoimmune disease 9.8
30 rheumatoid arthritis 9.8
31 anxiety 9.8
32 autoimmune disease 1 9.8
33 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
34 autoimmune lymphoproliferative syndrome, type v 9.8
35 arthritis 9.8
36 b-cell lymphomas 9.8
37 dilated cardiomyopathy 9.8
38 colitis 9.8
39 atrial fibrillation 9.8
40 mucositis 9.8
41 disseminated intravascular coagulation 9.8
42 polyneuropathy 9.8
43 hypothyroidism 9.8
44 intrahepatic cholestasis 9.8
45 hepatitis c 9.8
46 plasmacytoma 9.8
47 peritonitis 9.8
48 gastroduodenitis 9.8
49 acquired von willebrand syndrome 9.8
50 retinitis pigmentosa 7 9.7 LYZ TTR

Graphical network of the top 20 diseases related to Al Amyloidosis:



Diseases related to Al Amyloidosis

Symptoms & Phenotypes for Al Amyloidosis

Human phenotypes related to Al Amyloidosis:

31 (show top 50) (show all 54)
# Description HPO Frequency HPO Source Accession
1 renal insufficiency 31 frequent (33%) HP:0000083
2 proteinuria 31 frequent (33%) HP:0000093
3 nephrotic syndrome 31 frequent (33%) HP:0000100
4 enlarged kidney 31 frequent (33%) HP:0000105
5 nephropathy 31 frequent (33%) HP:0000112
6 macroglossia 31 occasional (7.5%) HP:0000158
7 xerostomia 31 occasional (7.5%) HP:0000217
8 hematuria 31 occasional (7.5%) HP:0000790
9 hypertension 31 occasional (7.5%) HP:0000822
10 adrenal insufficiency 31 occasional (7.5%) HP:0000846
11 goiter 31 occasional (7.5%) HP:0000853
12 purpura 31 occasional (7.5%) HP:0000979
13 keratoconjunctivitis sicca 31 occasional (7.5%) HP:0001097
14 polyneuropathy 31 occasional (7.5%) HP:0001271
15 congestive heart failure 31 frequent (33%) HP:0001635
16 hypertrophic cardiomyopathy 31 hallmark (90%) HP:0001639
17 bradycardia 31 occasional (7.5%) HP:0001662
18 asplenia 31 occasional (7.5%) HP:0001746
19 malabsorption 31 occasional (7.5%) HP:0002024
20 dyspnea 31 frequent (33%) HP:0002094
21 pleural effusion 31 occasional (7.5%) HP:0002202
22 gastrointestinal hemorrhage 31 occasional (7.5%) HP:0002239
23 hepatomegaly 31 frequent (33%) HP:0002240
24 autonomic dysregulation 31 occasional (7.5%) HP:0002271
25 aortic root aneurysm 31 occasional (7.5%) HP:0002616
26 lymphadenopathy 31 frequent (33%) HP:0002716
27 osteoarthritis 31 occasional (7.5%) HP:0002758
28 upper airway obstruction 31 occasional (7.5%) HP:0002781
29 arthralgia 31 frequent (33%) HP:0002829
30 abnormality of chromosome segregation 31 frequent (33%) HP:0002916
31 arthropathy 31 frequent (33%) HP:0003040
32 abnormal ekg 31 frequent (33%) HP:0003115
33 elevated alkaline phosphatase 31 frequent (33%) HP:0003155
34 decreased antibody level in blood 31 occasional (7.5%) HP:0004313
35 intermittent claudication 31 occasional (7.5%) HP:0004417
36 orthostatic hypotension due to autonomic dysfunction 31 occasional (7.5%) HP:0004926
37 autonomic bladder dysfunction 31 occasional (7.5%) HP:0005341
38 monoclonal immunoglobulin m proteinemia 31 frequent (33%) HP:0005508
39 abnormality of bone marrow cell morphology 31 occasional (7.5%) HP:0005561
40 interstitial pulmonary abnormality 31 frequent (33%) HP:0006530
41 multiple myeloma 31 frequent (33%) HP:0006775
42 abnormal blistering of the skin 31 occasional (7.5%) HP:0008066
43 abnormality of the submandibular glands 31 occasional (7.5%) HP:0010287
44 mechanical ileus 31 occasional (7.5%) HP:0010676
45 edema of the lower limbs 31 frequent (33%) HP:0010741
46 plasmacytoma 31 occasional (7.5%) HP:0011857
47 acute infectious pneumonia 31 frequent (33%) HP:0011949
48 hepatitis 31 occasional (7.5%) HP:0012115
49 fatigue 31 hallmark (90%) HP:0012378
50 chronic constipation 31 frequent (33%) HP:0012450

Drugs & Therapeutics for Al Amyloidosis

Drugs for Al Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
6
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
7
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
8
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
9
Morphine Approved, Investigational Phase 3 57-27-2 5288826
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
11
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
17
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
18
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
19
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
20
Dalteparin Approved Phase 3 9005-49-6
21
Daratumumab Approved Phase 3,Phase 1,Phase 2 945721-28-8
22 Ixazomib Approved, Investigational Phase 3,Phase 1,Phase 2 1072833-77-2
23
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
24
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
25
Glycine Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 56-40-6 750
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
28 Analgesics Phase 3,Phase 2
29 Alkylating Agents Phase 3,Phase 1,Phase 2
30 glucocorticoids Phase 3,Phase 2,Phase 1
31
protease inhibitors Phase 3,Phase 2,Phase 1
32 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
33 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
34 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
35 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
36 Anesthetics Phase 3
37 Hormone Antagonists Phase 3,Phase 2,Phase 1
38 Anesthetics, Dissociative Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
42 Hormones Phase 3,Phase 2,Phase 1
43 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
47 Antiemetics Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Excitatory Amino Acid Antagonists Phase 3
50 Excitatory Amino Acids Phase 3

Interventional clinical trials:

(show top 50) (show all 180)

# Name Status NCT ID Phase Drugs
1 Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy Not yet recruiting NCT03333551 Phase 4 F18 Florbetapir (amyvid) cardiac PET/CT imaging
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Completed NCT01998503 Phase 3 Bortezomib;dexamethasone;Melphalan
4 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3 Melphalan;Dexamethasone
5 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3 dexamethasone;melphalan
6 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
7 A Trial for Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3 BMDex
8 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
15 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
17 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
22 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Recruiting NCT03201965 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone, 40 mg;Daratumumab
23 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis Recruiting NCT01659658 Phase 3 IXAZOMIB;Dexamethasone;Melphalan;Cyclophosphamide;Thalidomide;Lenalidomide
24 The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis Active, not recruiting NCT02312206 Phase 3 NEOD001
25 A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy Not yet recruiting NCT03474458 Phase 2, Phase 3 Doxycycline;Standard of care therapy
26 Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib Terminated NCT02489500 Phase 3 Bortezomib;Melphalan;Neupogen
27 Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis Unknown status NCT01511263 Phase 2 Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
28 Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis Unknown status NCT01510613 Phase 2 Pomalidomide and Dexamethasone
29 Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) Unknown status NCT00981708 Phase 1, Phase 2 Lenalidomide, Dexamethasone and Cyclophosphamide
30 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
31 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction Completed NCT00547365 Phase 1, Phase 2
32 A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis Completed NCT00883623 Phase 2 Lenalidomide
33 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00679367 Phase 2 dexamethasone;lenalidomide;melphalan
34 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00091260 Phase 2 dexamethasone;lenalidomide
35 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2 dexamethasone
36 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00790647 Phase 2 bortezomib;melphalan
37 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Completed NCT01072773 Phase 2 bortezomib;cyclophosphamide;dexamethasone
38 Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis Completed NCT00166413 Phase 2 CC-5013
39 Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis Completed NCT00607581 Phase 2 cyclophosphamide;lenalidomide;dexamethasone
40 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003853 Phase 2 4'-iodo-4'-deoxydoxorubicin
41 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00564889 Phase 2 cyclophosphamide;dexamethasone;lenalidomide
42 Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis Completed NCT00089167 Phase 2 dexamethasone;melphalan;thalidomide
43 High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003353 Phase 2 melphalan
44 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Completed NCT00064337 Phase 2 cyclophosphamide;dexamethasone;melphalan;thalidomide
45 Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Completed NCT01194791 Phase 2 Lenalidomide;Cyclophosphamide;Dexamethasone
46 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Completed NCT00007995 Phase 2 busulfan;cyclophosphamide;melphalan
47 A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) Completed NCT02015312 Phase 2 Epigallocatechin-3-gallate (EGCG);Placebo
48 Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Completed NCT01527032 Phase 2 melphalan, thalidomide and dexamethasone
49 Autologous Stem Cell Rescue for Primary Amyloidosis Completed NCT00186407 Phase 2
50 Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis Completed NCT00017680 Phase 2 Melphalan

Search NIH Clinical Center for Al Amyloidosis

Genetic Tests for Al Amyloidosis

Anatomical Context for Al Amyloidosis

MalaCards organs/tissues related to Al Amyloidosis:

38
Bone, Bone Marrow, Liver, Kidney, Heart, Skin, Testes

Publications for Al Amyloidosis

Articles related to Al Amyloidosis:

(show top 50) (show all 579)
# Title Authors Year
1
Elevation of Plasmin-I+2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis. ( 29321425 )
2018
2
Venetoclax induced a complete response in a patient with AL amyloidosis plateaued on CyBorD. ( 29351984 )
2018
3
Atraumatic Splenic Rupture Due to Ectopic Extramedullary Hematopoiesis after Autologous Stem Cell Transplantation in a Patient with AL Amyloidosis. ( 29093392 )
2018
4
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. ( 29101236 )
2018
5
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis. ( 29386197 )
2018
6
Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. ( 29430701 )
2018
7
AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone-binding immunoglobulin: a new possible perspective. ( 28805259 )
2017
8
Acquired von Willebrand Syndrome Associated to Secondary IgM MGUS Emerging after Autologous Stem Cell Transplantation for AL Amyloidosis. ( 28512563 )
2017
9
Recurrent diffuse gastric bleeding as a leading symptom ofA gastrointestinal AL amyloidosis. ( 29212103 )
2017
10
Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected? ( 28737209 )
2017
11
Analysis of deposited peptides in amyloid lesions of AL amyloidosis by mass spectrometry. ( 28679987 )
2017
12
Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. ( 29269794 )
2017
13
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma. ( 29282382 )
2017
14
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. ( 28698204 )
2017
15
Light Chain (AL) Amyloidosis: The Journey to Diagnosis. ( 28808991 )
2017
16
Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. ( 28758811 )
2017
17
Attitudes about when and how to treat patients with AL amyloidosis: an international survey. ( 28857614 )
2017
18
News in AL Amyloidosis ASH 2016: AA rapidly evolving field of investigation. ( 28725274 )
2017
19
CKD stage V in AL amyloidosis: is it too late to treat? Maybe not. ( 29153137 )
2017
20
Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. ( 28648672 )
2017
21
Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review. ( 28056871 )
2017
22
Role of<sup>99m</sup>Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis. ( 29082513 )
2017
23
AL amyloidosis: from molecular mechanisms to targeted therapies. ( 29222231 )
2017
24
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. ( 27729322 )
2017
25
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. ( 28699650 )
2017
26
Correction: Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. ( 29107944 )
2017
27
Pathology and diagnosis of renal non-AL amyloidosis. ( 28828707 )
2017
28
Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. ( 29067795 )
2017
29
Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. ( 28926601 )
2017
30
Case report: One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma. ( 29390268 )
2017
31
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. ( 28832959 )
2017
32
Temporary Biventricular Assist Device to Bridge a Patient With Cardiogenic Shock Due to AL Amyloidosis to Heart Transplantation. ( 29230849 )
2017
33
Diffuse Peritoneal and Bowel Wall Infiltration by Light Chain-AL Amyloidosis with Omental Calcification Mimicking Abdominal Carcinomatosis - An Elderly Female with Incidental Finding of Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS). ( 29176541 )
2017
34
Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. ( 28701686 )
2017
35
The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. ( 28737773 )
2017
36
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. ( 28850697 )
2017
37
Echocardiography as the first diagnostic clue to rapidly progressive systemic AL amyloidosis associated with multiple site thrombosis. A case report. ( 29197924 )
2017
38
Budd Chiari syndrome associated with AL amyloidosis: a coagulation paradox. ( 29219632 )
2017
39
Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. ( 28754546 )
2017
40
Unravelling hypothyroidism in AL amyloidosis: Authors' reply. ( 28861923 )
2017
41
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. ( 28807981 )
2017
42
The long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency. ( 29093408 )
2017
43
Monoclonal IgM-related AL amyloidosis. ( 27825470 )
2016
44
99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis. ( 27351183 )
2016
45
Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. ( 27288311 )
2016
46
Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. ( 26961452 )
2016
47
Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. ( 27412900 )
2016
48
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. ( 27647123 )
2016
49
New and developing therapies for AL amyloidosis. ( 28002971 )
2016
50
Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. ( 27183092 )
2016

Variations for Al Amyloidosis

Expression for Al Amyloidosis

Search GEO for disease gene expression data for Al Amyloidosis.

Pathways for Al Amyloidosis

Pathways related to Al Amyloidosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 IL3 LGALS3 LYZ MMP1 TTR VWF
2 10.55 LGALS3 MMP1

GO Terms for Al Amyloidosis

Cellular components related to Al Amyloidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 IL3 LGALS3 LYZ TTR
2 azurophil granule lumen GO:0035578 9.16 LYZ TTR
3 extracellular matrix GO:0031012 9.13 LGALS3 MMP1 VWF
4 extracellular region GO:0005576 9.1 IL3 LGALS3 LYZ MMP1 TTR VWF

Biological processes related to Al Amyloidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.13 LGALS3 LYZ TTR
2 cellular protein metabolic process GO:0044267 8.8 LYZ MMP1 TTR

Sources for Al Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....